Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2024-05-21 Legal Proceedings Report
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
PRTC's Vedanta Begins Phase 3 of VE303 in C. diff
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 1862P' and concludes with information about 'Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This strongly indicates the document is a regulatory news service announcement. The content itself is a press release from PureTech Health plc announcing a clinical trial milestone for its Founded Entity, Vedanta Biosciences. This type of announcement, which is a general corporate update distributed via a regulatory feed but doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or DIV), is best classified as a Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it contained financial results, but here it is purely operational/clinical news. Given the explicit RNS header and footer, RNS is the most appropriate general regulatory announcement category.
2024-05-21 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, PureTech Health plc. It reports the issuance of a press release about the launch of a proposed $100 million tender offer. The document itself is short (1708 characters) and primarily serves to furnish the press release as an exhibit. There is no substantive financial data or detailed report content within this filing. The key content is an announcement of a financing-related event (tender offer). According to the classification rules, since this is an announcement related to financing activities (tender offer) and not a full report, it fits best under Capital/Financing Update (CAP).
2024-05-20 English
Shareholder Circular regarding Proposed Tender Offer
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a comprehensive 'Circular' that details a 'PROPOSED CAPITAL RETURN OF $100 MILLION TO SHAREHOLDERS BY WAY OF A TENDER OFFER' and includes a 'NOTICE OF GENERAL MEETING'. It provides extensive instructions for shareholders on how to participate in the tender offer (for Ordinary Shares and ADSs) and how to vote at the upcoming General Meeting using a Form of Proxy. Documents that solicit shareholder votes for a meeting, especially when combined with a major corporate action like a tender offer or capital return, are typically classified as Proxy Solicitation & Information Statements (DEF 14A or PSI). Since this document explicitly contains the 'NOTICE OF GENERAL MEETING' and detailed instructions for proxy voting ('Form of Proxy'), it strongly aligns with the definition of a Proxy Solicitation & Information Statement (PSI). While it also discusses a capital return (CAP), the primary function of this specific document format (a Circular containing both the offer details and the meeting notice/proxy instructions) points to PSI.
2024-05-20 English
Tender Offer
M&A Activity Classification · 100% confidence The document is an official announcement (RNS Number: 0043P) detailing the 'Launch of Proposed $100 million Tender Offer' and a 'Notice of General Meeting'. A tender offer is a proposal to buy back shares, which is a form of capital structure change or transaction in own shares. Since the document details the mechanics, pricing, closing dates, and conditions (including shareholder approval at a General Meeting) for a tender offer, it directly relates to capital/financing activities and share transactions. The definition for 'Capital/Financing Update' (CAP) covers fundraising/financing activities, and 'Transaction in Own Shares' (POS) covers share repurchase. Given the primary focus is the tender offer structure (a mechanism for share repurchase), POS is highly relevant. However, tender offers often involve significant capital structure decisions and are announced via regulatory filings. Since the document is a comprehensive announcement detailing the terms of a major transaction involving the purchase of the company's own shares, 'Transaction in Own Shares' (POS) is the most specific fit, although 'Capital/Financing Update' (CAP) is also plausible. Given the explicit mention of purchasing Ordinary Shares for cash, POS is selected. The document is a full announcement, not just a notice that a report is attached, so RPA/RNS is not the primary classification.
2024-05-20 English
SC TO-I Filing
Regulatory Filings
2024-05-20 English
Interim accounts made up to 2024-05-07
Regulatory Filings
2024-05-17 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.